Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells.

Hau AM, Gupta S, Leivo MZ, Nakashima K, Macias J, Zhou W, Hodge A, Wulfkuhle J, Conkright B, Bhuvaneshwar K, Rao S, Madhavan S, Petricoin EF 3rd, Hansel DE.

Am J Pathol. 2019 Jun 11. pii: S0002-9440(19)30079-3. doi: 10.1016/j.ajpath.2019.05.010. [Epub ahead of print]

PMID:
31199921
2.

A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.

Gupta S, Sosa CP, Kosari F, Folpe A, Bhinge KN, Yang L, Agahi A, Johnson SH, Frank I, Boorjian SA, Hansel DE, Al-Ahmadie HA, Reuter VE, Vasmatzis G, Jimenez RE, Herrera-Hernandez L, Cheville JC.

Hum Pathol. 2019 Jun;88:48-59. doi: 10.1016/j.humpath.2019.03.007. Epub 2019 Apr 1.

PMID:
30946934
3.

[Comparison of UICC and AJCC 8th edition TNM classifications in uropathology].

Compérat E, Varinot J, Eymerit C, Paner GP, Hansel DE, Amin MB, Moroch J.

Ann Pathol. 2019 Apr;39(2):158-166. doi: 10.1016/j.annpat.2018.12.005. Epub 2019 Jan 30. French.

PMID:
30711335
4.

Non-urothelial carcinomas of the bladder.

Park S, Reuter VE, Hansel DE.

Histopathology. 2019 Jan;74(1):97-111. doi: 10.1111/his.13719. Review.

PMID:
30565306
5.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

6.

Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2?

Bindayi A, Mcdonald ML, Beksac AT, Rivera-Sanfeliz G, Shabaik A, Hughes F, Aganovic L, Hansel DE, Derweesh IH.

Turk J Urol. 2018 Jul;44(4):316-322. doi: 10.5152/tud.2018.28938.

7.

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.

Gupta S, Sahu D, Bomalaski JS, Frank I, Boorjian SA, Thapa P, Cheville JC, Hansel DE.

Endocr Pathol. 2018 Sep;29(3):236-241. doi: 10.1007/s12022-018-9516-9.

PMID:
29453600
8.

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.

Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB.

Eur Urol. 2018 Apr;73(4):560-569. doi: 10.1016/j.eururo.2017.12.018. Epub 2018 Jan 9. Review.

PMID:
29325693
9.

Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.

Leivo MZ, Sahoo D, Hamilton Z, Mirsadraei L, Shabaik A, Parsons JK, Kader AK, Derweesh I, Kane C, Hansel DE.

Am J Surg Pathol. 2018 Jan;42(1):e1-e10. doi: 10.1097/PAS.0000000000000964.

PMID:
29076872
10.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

11.

Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.

Mirsadraei L, Hodkoff A, Jones K, Shabaik A, Kader AK, Saenz CC, Montironi R, Tacha DE, Fadare O, Hansel DE.

Arch Pathol Lab Med. 2018 Feb;142(2):168-177. doi: 10.5858/arpa.2017-0004-OA. Epub 2017 Aug 10.

PMID:
28795841
12.

Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.

Sahu D, Lotan Y, Wittmann B, Neri B, Hansel DE.

Cancer Med. 2017 Sep;6(9):2106-2120. doi: 10.1002/cam4.1109. Epub 2017 Aug 1.

13.

Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.

Duex JE, Owens C, Chauca-Diaz A, Dancik GM, Vanderlinden LA, Ghosh D, Leivo MZ, Hansel DE, Theodorescu D.

Cancer Res. 2017 Sep 15;77(18):4858-4867. doi: 10.1158/0008-5472.CAN-17-0367. Epub 2017 Jul 3.

14.

Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition.

Hau AM, Nakasaki M, Nakashima K, Krish G, Hansel DE.

Urol Oncol. 2017 Oct;35(10):593-599. doi: 10.1016/j.urolonc.2017.03.025. Epub 2017 Apr 18.

PMID:
28427860
15.

The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment.

Hansel DE.

J Urol. 2017 Feb;197(2S):S140-S141. doi: 10.1016/j.juro.2016.11.028. Epub 2016 Dec 20. No abstract available.

PMID:
28010973
16.

Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.

Sahu D, Gupta S, Hau AM, Nakashima K, Leivo MZ, Searles SC, Elson P, Bomalaski JS, Casteel DE, Boss GR, Hansel DE.

Am J Pathol. 2017 Jan;187(1):200-213. doi: 10.1016/j.ajpath.2016.09.004. Epub 2016 Dec 9.

17.

mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.

Hau AM, Leivo MZ, Gilder AS, Hu JJ, Gonias SL, Hansel DE.

Cell Signal. 2017 Jan;29:96-106. doi: 10.1016/j.cellsig.2016.10.010. Epub 2016 Oct 21.

PMID:
27777073
18.

Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?

Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE.

Urology. 2017 Apr;102:7-16. doi: 10.1016/j.urology.2016.10.014. Epub 2016 Oct 18. Review.

PMID:
27769917
19.

A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.

Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE.

Pathology. 2016 Oct;48(6):543-9. doi: 10.1016/j.pathol.2016.05.008. Epub 2016 Sep 2.

20.

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA.

Cancer Cell. 2016 Sep 12;30(3):432-443. doi: 10.1016/j.ccell.2016.08.002. Epub 2016 Sep 1.

21.

The Emerging Molecular Landscape of Urothelial Carcinoma.

Solomon JP, Hansel DE.

Surg Pathol Clin. 2016 Sep;9(3):391-404. doi: 10.1016/j.path.2016.04.004. Review.

PMID:
27523968
22.

Adrenal Pathology in the Adult: A Urological Pathologist's Perspective.

Hansel DE, Reuter VE.

Adv Anat Pathol. 2016 Sep;23(5):273-84. doi: 10.1097/PAP.0000000000000120. Review.

PMID:
27438375
23.

Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.

Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE.

Arch Pathol Lab Med. 2016 Jun;140(6):543-51. doi: 10.5858/arpa.2015-0085-OA. Epub 2016 Mar 31.

PMID:
27031776
24.

Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.

Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Compérat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ.

Histopathology. 2016 Sep;69(3):441-9. doi: 10.1111/his.12976. Epub 2016 May 24.

25.

Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.

Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, Howe PH, Hansel DE.

Am J Pathol. 2016 May;186(5):1351-60. doi: 10.1016/j.ajpath.2016.01.008. Epub 2016 Mar 14.

26.

Morphologic and Molecular Characteristics of Bladder Cancer.

Solomon JP, Hansel DE.

Surg Pathol Clin. 2015 Dec;8(4):663-76. doi: 10.1016/j.path.2015.07.003. Review.

PMID:
26612220
27.

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.

Ren Y, Wang M, Couto S, Hansel DE, Miller K, Lopez-Girona A, Bjorklund CC, Gandhi AK, Thakurta A, Chopra R, Breider M.

Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):695-702.

28.

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.

Ikeda S, Hansel DE, Kurzrock R.

Cancer Treat Rev. 2015 Sep;41(8):699-706. doi: 10.1016/j.ctrv.2015.06.004. Epub 2015 Jun 23. Review.

29.

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M.

Nature. 2015 May 7;521(7550):94-8. doi: 10.1038/nature14395. Epub 2015 Apr 29.

30.

Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates.

Solomon JP, Hansel DE.

Adv Anat Pathol. 2015 Mar;22(2):102-12. doi: 10.1097/PAP.0000000000000050. Review.

PMID:
25664945
31.

CD117⁺ cells in the circulation are predictive of advanced prostate cancer.

Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE, Heston WD, Stephenson AJ, Klein EA, Byzova TV.

Oncotarget. 2015 Jan 30;6(3):1889-97.

32.

Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP, Al-Ahmadie HA, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, Cheville JC, Kristiansen G, Cote RJ, Delahunt B, Eble JN, Genega EM, Gulmann C, Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, Netto GJ, Oliva E, Rao P, Ro JY, Srigley JR, Tickoo SK, Tsuzuki T, Umar SA, Van der Kwast T, Young RH, Soloway MS.

Mod Pathol. 2015 May;28(5):612-30. doi: 10.1038/modpathol.2014.158. Epub 2014 Nov 21. Review.

33.

Micropapillary bladder cancer: current treatment patterns and review of the literature.

Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM.

Urol Oncol. 2014 Aug;32(6):826-32. doi: 10.1016/j.urolonc.2014.01.020. Epub 2014 Jun 13. Review.

34.

Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.

Paner GP, Annaiah C, Gulmann C, Rao P, Ro JY, Hansel DE, Shen SS, Lopez-Beltran A, Aron M, Luthringer DJ, De Peralta-Venturina M, Cho Y, Amin MB.

Hum Pathol. 2014 Jul;45(7):1473-82. doi: 10.1016/j.humpath.2014.02.024. Epub 2014 Mar 14.

PMID:
24780825
35.

Highlights from the first symposium on upper tract urothelial carcinoma.

Matin SF, Shariat SF, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP.

Urol Oncol. 2014 Apr;32(3):309-16. doi: 10.1016/j.urolonc.2013.08.029. Epub 2014 Jan 4. Review.

PMID:
24397995
36.

Uroplakin II outperforms uroplakin III in diagnostically challenging settings.

Smith SC, Mohanty SK, Kunju LP, Chang E, Chung F, Carvalho JC, Paner GP, Hansel DE, Luthringer DJ, de Peralta-Ventrurina MN, Amin MB.

Histopathology. 2014 Jul;65(1):132-8. doi: 10.1111/his.12360. Epub 2014 Feb 25.

37.

Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion.

Gupta S, Hau AM, Beach JR, Harwalker J, Mantuano E, Gonias SL, Egelhoff TT, Hansel DE.

PLoS One. 2013 Nov 27;8(11):e81081. doi: 10.1371/journal.pone.0081081. eCollection 2013.

38.

Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.

Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB.

Am J Surg Pathol. 2013 Dec;37(12):1815-23. doi: 10.1097/PAS.0000000000000114.

PMID:
24225842
39.

Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists.

Ananthanarayanan V, Pan Y, Tretiakova M, Amin MB, Cheng L, Epstein JI, Grignon DJ, Hansel DE, Jimenez RE, McKenney JK, Montironi R, Oliva E, Osunkoya AO, Rao P, Reuter VE, Ro JY, Shen SS, Srigley JR, Tsuzuki T, Yao JL, Antic T, Haber M, Taxy JB, Paner GP.

Am J Surg Pathol. 2014 Feb;38(2):167-75. doi: 10.1097/PAS.0000000000000096.

PMID:
24145655
40.

Gene profiling suggests a common evolution of bladder cancer subtypes.

Hansel DE, Zhang Z, Petillo D, Teh BT.

BMC Med Genomics. 2013 Oct 17;6:42. doi: 10.1186/1755-8794-6-42.

41.

Diagnostically challenging cases: what are atypia and dysplasia?

Sanfrancesco J, Jones JS, Hansel DE.

Urol Clin North Am. 2013 May;40(2):281-93. doi: 10.1016/j.ucl.2013.01.006. Epub 2013 Feb 26.

42.

Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.

Hansel DE, Miller JS, Cookson MS, Chang SS.

Urology. 2013 Jun;81(6):1123-30. doi: 10.1016/j.urology.2013.01.027. Epub 2013 Mar 19. Review.

43.

Editorial comment.

Hansel DE.

J Urol. 2013 May;189(5):1660-1. doi: 10.1016/j.juro.2012.11.194. Epub 2013 Feb 16. No abstract available.

PMID:
23419938
44.

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.

Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383. Epub 2013 Feb 12.

45.

Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma.

Patel AR, Cohn JA, Abd El Latif A, Miocinovic R, Steinberg GD, Paner GP, Hansel DE.

J Urol. 2013 Jan;189(1):53-8. doi: 10.1016/j.juro.2012.09.006. Epub 2012 Nov 16.

PMID:
23164389
46.

Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.

Gruver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, Osunkoya AO, McKenney JK, Hansel DE.

Arch Pathol Lab Med. 2012 Nov;136(11):1339-46. doi: 10.5858/arpa.2011-0575-OA.

PMID:
23106579
47.

A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.

Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van der Kwast TH.

Eur Urol. 2013 Feb;63(2):321-32. doi: 10.1016/j.eururo.2012.10.008. Epub 2012 Oct 12. Review.

PMID:
23088996
48.

The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy.

Abd El-Latif A, Watts KE, Elson P, Fergany A, Hansel DE.

J Urol. 2013 Apr;189(4):1263-7. doi: 10.1016/j.juro.2012.10.054. Epub 2012 Oct 17.

PMID:
23085297
49.

ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.

Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, Epstein JI, Reuter VE; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):16-35. doi: 10.1016/j.eururo.2012.09.063. Epub 2012 Oct 5. Review.

PMID:
23083804
50.

Small cell bladder cancer: biology and management.

Fahed E, Hansel DE, Raghavan D, Quinn DI, Dorff TB.

Semin Oncol. 2012 Oct;39(5):615-8. doi: 10.1053/j.seminoncol.2012.08.009. Review.

PMID:
23040258

Supplemental Content

Loading ...
Support Center